Evidence map›Paper›PMID 30384441›Full record

ReviewInternational journal of molecular sciences2018

Regulating Apoptosis by Degradation: The N-End Rule-Mediated Regulation of Apoptotic Proteolytic Fragments in Mammalian Cells.

Mohamed A Eldeeb, Richard P Fahlman, Mansoore Esmaili, Mohamed A Ragheb

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. tRNACell chemical biology · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Degradation of proteins with N-terminal glycine.Nature structural & molecular biology · 2019
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Mohamed A EldeebDepartment of Chemistry (Biochemistry Division), Faculty of Science, Cairo University, Giza 12613, Egypt. eldeeb@ualberta.ca.ORCID 0000-0001-9671-9340
Richard P FahlmanDepartment of Biochemistry, University of Alberta, Edmonton, AB T6G 2H7, Canada. rfahlman@ualberta.ca.
Mansoore EsmailiDepartment of Biochemistry, University of Alberta, Edmonton, AB T6G 2H7, Canada. esmaili@ualberta.ca.
Mohamed A RaghebDepartment of Chemistry (Biochemistry Division), Faculty of Science, Cairo University, Giza 12613, Egypt. mattia@sci.cu.edu.eg.
University of Alberta · CACairo University · EGMontreal Neurological Institute and Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A pivotal hallmark of some cancer cells is the evasion of apoptotic cell death. Importantly, the initiation of apoptosis often results in the activation of caspases, which, in turn, culminates in the generation of proteolytically-activated protein fragments with potentially new or altered roles. Recent investigations have revealed that the activity of a significant number of the protease-generated, activated, pro-apoptotic protein fragments can be curbed via their selective degradation by the N-end rule degradation pathways. Of note, previous work revealed that several proteolytically-generated, pro-apoptotic fragments are unstable in cells, as their destabilizing N-termini target them for proteasomal degradation via the N-end rule degradation pathways. Remarkably, previous studies also showed that the proteolytically-generated anti-apoptotic Lyn kinase protein fragment is targeted for degradation by the UBR1/UBR2 E3 ubiquitin ligases of the N-end rule pathway in chronic myeloid leukemia cells. Crucially, the degradation of cleaved fragment of Lyn by the N-end rule counters imatinib resistance in these cells, implicating a possible linkage between the N-end rule degradation pathway and imatinib resistance. Herein, we highlight recent studies on the role of the N-end rule proteolytic pathways in regulating apoptosis in mammalian cells, and also discuss some possible future directions with respect to apoptotic proteolysis signaling.

Indexed as

ApoptosisNeoplasm ProteinsPeptidesProteolysisAnimalsDrug Resistance, NeoplasmHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveImatinib MesylateNeoplasm ProteinsPeptidesapoptosiscancer biologycaspasescell deathN-end-ruleN-terminal arginylationproteasesprotein degradationproteolysisubiquitination

Identifiers

PMID30384441
PMCPMC6274719
OpenAlexW2898898243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.